- 09/29/2017
- eisai presents results of phase iii trial of lenvima® (lenvatinib) in unresectable hepatocellular carcinoma in oral session at 20th csco annual meeting
- 09/19/2017
- eisai presents results of phase iii clinical study of lenvima® (lenvatinib) in unresectable hepatocellular carcinoma at 11th ilca annual conference
- 09/15/2017
- eisai china joins hands with partners to kick off “alzheimer’s care” for the well-being of chinese families
- 09/11/2017
- eisai selected for fifth consecutive year of membership in dow jones sustainability asia pacific index 2017
- 09/08/2017
- conclusion of development collaboration agreement for lenvima® (lenvatinib mesylate) and opdivo® (nivolumab) combination therapy for treatment of hepatocellular carcinoma
- 09/02/2017
- eisai (china) listed in 2016 china top 100 pharmaceutical companies
- 07/27/2017
- u.s. fda approves additional use of antiepileptic drug fycompa® as monotherapy for partial-onset seizures
- 07/25/2017
- eisai submits simultaneous applications in the united states and europe for lenvatinib in hepatocellular carcinoma
- 06/05/2017
- eisai to present results of phase iii trial of lenvima® (lenvatinib) as first-line treatment for unresectable hepatocellular carcinoma in oral session at 53rd asco annual meeting
- 06/05/2017
- eisai to present results of phase ib/ii study of anticancer agent lenvima® (lenvatinib) in combination with anti-pd-1 antibody pembrolizumab for the treatment of endometrial carcinoma at 53rd asco ann